Immune Benefits of Consumption of Dairy Yogurt in Elderly

Yonsei University200 enrolled

Overview

To investigate the impact of consuming dairy yogurt on immun function including natural killer (NK) cell activity, circulating levels of cytokines, and immunoglobulin (Ig) in elderly.

A randomized, open-labelled, placebo-controlled study was conducted on 200 nondiabetic, nonobese and elderly (≥60 years) subjects. Over a twelve-week period, the test group consumed one bottle (120 mL) of dairy yogurt each day, whereas the placebo group consumed same volume of low fat milk daily. NK cell activity (%) was measured based on the ratios of effector cells (E; peripheral blood mononuclear cells, PBMCs) from each participant to target cells (T; K562 cells) at E:T= 10:1, 5:1, 2.5:1, 1.25:1 or 0.625:1. In addition, cytokines and immunoglobulin levels measured using commercial kits as manufacturer's instruction.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

200

Conditions

Immune Deficiency

Interventions

Probiotic yogurtDIETARY_SUPPLEMENT

120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum

PlaceboDIETARY_SUPPLEMENT

120 mL of low-fat milk

Eligibility

Sex: ALLMin age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Able to give informed consent * Over 60 years old without any health problems * The levels of white blood cells within range 4x10\^3/μL\~10x10\^3/μL Exclusion Criteria: * Individuals who get a cold * Diabetes * Hypersensitivity or disease history for milk protein * Epilepsy, neurological, or psychological disease * Alcoholism or drug addiction * Liver disease or severe kidney failure disease * Inflammation-related disease * Consumption of other test products or drugs within 1 month prior to screening * Regular consumption of immune-related functional foods including yogurt or milk within 1 month prior to screening * History of inflammation-related disease or taking medication to treat inflammation-related disease within 1 month prior to screening * History of cancer within 5 years * Any inappropriate condition

Locations (1)

Yonsei University

Seoul, South Korea

Outcomes

Primary Outcomes

Natural killer cell activity

Time frame: At baseline

Natural killer cell activity

Time frame: At 12-week follow-up

Change from baseline natural killer cell activity at 12-week

Time frame: At baseline and 12-week follow-up

Secondary Outcomes

White blood cell

Time frame: At baseline

White blood cell

Time frame: At 12-week follow-up

Change from baseline white blood cell at 12-week

Time frame: At baseline and 12-week follow-up

Interleukin-12

Time frame: At baseline

Interleukin-12

Time frame: At 12-week follow-up

Change from baseline Interleukin-12 at 12-week

Time frame: At baseline and 12-week follow-up

Interferon-gamma

Time frame: At baseline

Interferon-gamma

Time frame: At 12-week follow-up

Change from baseline Interferon-gamma at 12-week

Time frame: At baseline and 12-week follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.